Kymera Therapeutics, Inc.
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing oral medicines, primarily for patients with immune-inflammatory diseases. It uses targeted protein degradation, a small-molecule approach designed to engage the body’s cellular recycling system to eliminate disease-causing proteins. Its disclosed immunology programs target STAT6, IRF5 and IRAK4. Its candidates include KT-621, in Phase 2b trials for atopic dermatitis and asthma, and KT-579, in Phase 1 testing. Kymera is also collaborating with Sanofi on an IRAK4 degrader and with Gilead Sciences on molecular glue degraders targeting CDK2, with potential oncology applications. Kymera conducts drug discovery and preclinical research and develops its own candidates, while collaboration partners may take responsibility for later development, manufacturing and commercialization under their agreements. It relies on third-party manufacturers for drug substance and finished drug products. The company is headquartered in Watertown, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $KYMR in the last 30 days.
See all $KYMR insider activity →Kymera Therapeutics is preparing for trial results of its eczema drug, KT-621, which targets STAT6. Analysts project potential sales of nearly $4 billion by 2035. The drug aims to treat moderate-to-severe eczema without the safety risks of current oral therapies. Kymera's stock has risen over 70% this year, but success hinges on the upcoming BROADEN2 trial results.
Barclays reaffirmed its Overweight rating on Kymera Therapeutics and increased its price target to $170 from $139, suggesting a 34.2% upside from the last close. Other recent analyst targets for the company range from $116 to $150.
Truist Securities kept its Buy rating on Kymera Therapeutics and increased its price target to $150 from $136, suggesting a 22.3% upside from the last close of $122.60. Recent analyst targets for the company range from $116 to $150.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning KYMR (Kymera Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent KYMR coverage spans financial news, earnings and technology.
Trial outcome risk is binary for KYMR’s valuation, with efficacy and safety expectations driving sentiment into the readout.
Barclays reaffirmed its Overweight rating on Kymera Therapeutics and increased its price target to $170 from $139, suggesting a 34.2% upside from the last close. Other recent analyst targets for the company range from $116 to $150.
Truist Securities kept its Buy rating on Kymera Therapeutics and increased its price target to $150 from $136, suggesting a 22.3% upside from the last close of $122.60. Recent analyst targets for the company range from $116 to $150.
RBC Capital maintained its Sector Perform rating on Kymera Therapeutics but raised its price target to $116 from $112, implying a 5.4% downside from the last close. Other recent analyst targets for the company range from $139 to $150.
BTIG kept its Buy rating on Kymera Therapeutics and increased its price target to $139 from $134. This implies a 13.4% upside from the last close of $122.60. Other recent analyst targets for the stock range from $140 to $150.
AlphAI scores every news story that mentions KYMR with an AI model for sentiment and relevance, and aggregates insider trades from Kymera Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Kymera Therapeutics is preparing for trial results of its eczema drug, KT-621, which targets STAT6. Analysts project potential sales of nearly $4 billion by 2035. The drug aims to treat moderate-to-severe eczema without the safety risks of current oral therapies. Kymera's stock has risen over 70% this year, but success hinges on the upcoming BROADEN2 trial results.
Barclays reaffirmed its Overweight rating on Kymera Therapeutics and increased its price target to $170 from $139, suggesting a 34.2% upside from the last close. Other recent analyst targets for the company range from $116 to $150.
Truist Securities kept its Buy rating on Kymera Therapeutics and increased its price target to $150 from $136, suggesting a 22.3% upside from the last close of $122.60. Recent analyst targets for the company range from $116 to $150.
RBC Capital maintained its Sector Perform rating on Kymera Therapeutics but raised its price target to $116 from $112, implying a 5.4% downside from the last close. Other recent analyst targets for the company range from $139 to $150.
BTIG kept its Buy rating on Kymera Therapeutics and increased its price target to $139 from $134. This implies a 13.4% upside from the last close of $122.60. Other recent analyst targets for the stock range from $140 to $150.
Oppenheimer raised its price target for Kymera Therapeutics (NASDAQ:KYMR) to $140 from $125, citing positive drug trial results and Q3 financials. The stock is near its 52-week high. Kymera reported a Q3 loss of $1.32 per share, slightly missing estimates, but has $1.6B in cash. Brookline Capital also raised its target to $132.
Brookline Capital raised its price target for Kymera Therapeutics (KYMR) to $132 from $111, citing reduced risks. The stock trades near its 52-week high at $121.50. The firm adjusted financial estimates, including increased net loss per share and decreased additional capital needed. Kymera reported a narrower-than-expected Q3 2026 loss and has $1.6B in cash.
Kymera Therapeutics (KYMR) reported Q3 2026 results, missing earnings but showing 90%+ target engagement for its IRF5 degrader KT-579. The stock rose 3.46% premarket. The company reported a net loss of $132M, up from $82.2M YoY, with R&D expenses increasing 73%. Kymera has $1.6B in cash, providing a runway into 2029. KT-579 showed promising Phase 1 data, with significant biomarker reductions and a favorable safety profile.
Kymera Therapeutics, Inc. (KYMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-re
Kymera Therapeutics (KYMR) will release Phase 1 trial results for KT-579 on October 29, 2026, alongside its Q3 financial results. KT-579 targets IRF5 for autoimmune diseases. A conference call is scheduled for 8:30 a.m. ET.
